Longitudinal Single Photon Emission Computed Tomography Neuroimaging as an Indication of Improvement in Psychiatric Disorders in a Community Psychiatric Practice.

Autor:	Thornton JF; Rossiter-Thornton Associates, Toronto, ON, Canada.; International Society of Applied Neuroimaging, Denver, CO, United States., Schneider H; International Society of Applied Neuroimaging, Denver, CO, United States.; Sheppard Clinic North, Vaughan, ON, Canada., Cohen PF; International Society of Applied Neuroimaging, Denver, CO, United States.; Nuclear Medicine, Lions Gate Hospital, Vancouver, BC, Canada.; Department of Radiology, University of British Columbia, Vancouver, BC, Canada., DeBruin S; Good Lion Imaging LLC, Columbia, MD, United States., Uszler JM; International Society of Applied Neuroimaging, Denver, CO, United States.; DrSPECTscan Inc., Lake Elsinore, CA, United States.; Department of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, United States., Siow YH; International Society of Applied Neuroimaging, Denver, CO, United States.; Nuclear Medicine, Southlake Regional Health Centre, Newmarket, ON, Canada., McLean MK; International Society of Applied Neuroimaging, Denver, CO, United States.; Private Practice, Toronto, ON, Canada., van Lierop MJ; International Society of Applied Neuroimaging, Denver, CO, United States.; Private Practice, Toronto, ON, Canada., Pavel DG; International Society of Applied Neuroimaging, Denver, CO, United States.; PathFinder Brain SPECT LLC, Deerfield, IL, United States., Henderson TA; International Society of Applied Neuroimaging, Denver, CO, United States.; Dr. Theodore Henderson, Inc., Denver, CO, United States.; The Synaptic Space, Inc., Denver, CO, United States.; Neuro-Luminance, Inc., Denver, CO, United States.
Jazyk:	angličtina
Zdroj:	Frontiers in psychiatry [Front Psychiatry] 2022 Mar 25; Vol. 13, pp. 787186. Date of Electronic Publication: 2022 Mar 25 (Print Publication: 2022).
DOI:	10.3389/fpsyt.2022.787186
Abstrakt:	In the community, there is a need to more objectively evaluate the response of common chronic psychiatric disorders to treatment. Brain single photon emission computed tomography (SPECT) indirectly measures cerebral functional activity by uptake of a radiotracer, which follows regional cerebral blood flow. Brain 3D Thresholded SPECT scans are thresholded three dimensional images derived from brain SPECT data. A retrospective community study of longitudinal (before and after treatment) brain 3D Thresholded SPECT scans of 73 patients with all-cause psychiatric disorders (most frequent diagnostic clusters: attention-deficit hyperactivity disorder, post-mild traumatic brain injury, affective disorders, psychotic disorders, post-viral chronic syndromes), shows these baseline SPECT scans predict improvement (non-worsening to large improvement) in clinical functioning with a sensitivity of 94% (95% confidence interval 86-98%) and a specificity of 67% (95% confidence interval 21-94%). In contrast, contemporaneous analysis by the same radiologist of conventional 2D reading of the same before and after treatment brain SPECT scan data of the same 73 patients, predicted improvement (non-worsening to large improvement) in clinical functioning with a sensitivity of only 26% (95% confidence interval 17-37%) although with a specificity of 100% (95% confidence interval 44-100%). These data suggest 3D Thresholded SPECT scans can provide the clinician with a more objective measure for verifying improvement in psychiatric disorders seen in the community, consistent with prior studies of SPECT as a measure of neurobiological change. Furthermore, these data suggest 3D Thresholded SPECT scans may have clinical application in guiding treatment and potentially improving outcomes. Competing Interests: SD is President at Good Lion Imaging LLC, a neuroimaging-related company. JU is the Medical Director of DrSpectScan.org, a clinical service corporation and derives 25% of his income from neuroimaging. Y-HS derives 10% of his income from neuroimaging. DP is deceased. TH is the president and principal owner of The Synaptic Space, a neuroimaging consulting firm. He is also CEO and Chairman of the Board of Neuro-Luminance Corporation, a medical service company. He is also president and principal owner of Dr. Theodore Henderson, Inc, a medical service company. TH has no ownership in, and receives no remuneration from, any neuroimaging company. No more than 5% of his income is derived from neuroimaging. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Thornton, Schneider, Cohen, DeBruin, Uszler, Siow, McLean, van Lierop, Pavel and Henderson.)
Databáze:	MEDLINE
Externí odkaz: